J&J announces Phase 3 LIBREXIA-STROKE trial results evaluating milvexian, an oral factor XIa inhibitor, for secondary stroke prevention.

Roche announces positive Phase 3 ALINA trial results showing Alecensa (alectinib) significantly improves disease-free survival in resected ALK-positive NSCLC.

AbbVie announces Phase 2 trial results showing navitoclax plus ruxolitinib achieves hematologic responses in patients with polycythemia vera resistant or intolerant to hydroxyurea.

Merck presents five-year overall survival data from KEYNOTE-177 trial showing sustained benefit of Keytruda as first-line treatment for MSI-H/dMMR colorectal cancer.

Pfizer announces Phase 3 ALLEGRO trial results showing ritlecitinib significantly promotes hair regrowth in adults and adolescents with alopecia areata.

AstraZeneca announces Phase 3 trial results showing roxadustat effectively treats anemia in patients receiving myelosuppressive chemotherapy for non-myeloid malignancies.

Novartis announces Phase 3 APPEAR-C3G trial results showing iptacopan significantly reduces proteinuria and improves kidney function in C3 glomerulopathy.

Gilead Sciences presents overall survival data from ASCENT trial showing Trodelvy (sacituzumab govitecan) provides significant survival benefit in metastatic TNBC.

J&J announces Phase 3 LIBREXIA-STROKE trial results evaluating milvexian, an oral factor XIa inhibitor, for secondary stroke prevention.

Roche announces positive Phase 3 ALINA trial results showing Alecensa (alectinib) significantly improves disease-free survival in resected ALK-positive NSCLC.

AbbVie announces Phase 2 trial results showing navitoclax plus ruxolitinib achieves hematologic responses in patients with polycythemia vera resistant or intolerant to hydroxyurea.

Merck presents five-year overall survival data from KEYNOTE-177 trial showing sustained benefit of Keytruda as first-line treatment for MSI-H/dMMR colorectal cancer.

Pfizer announces Phase 3 ALLEGRO trial results showing ritlecitinib significantly promotes hair regrowth in adults and adolescents with alopecia areata.

AstraZeneca announces Phase 3 trial results showing roxadustat effectively treats anemia in patients receiving myelosuppressive chemotherapy for non-myeloid malignancies.

Novartis announces Phase 3 APPEAR-C3G trial results showing iptacopan significantly reduces proteinuria and improves kidney function in C3 glomerulopathy.

Gilead Sciences presents overall survival data from ASCENT trial showing Trodelvy (sacituzumab govitecan) provides significant survival benefit in metastatic TNBC.

AstraZeneca reports five-year overall survival data from the ADAURA Phase 3 trial showing TAGRISSO (osimertinib) reduces the risk of death by 51% versus placebo in patients with resected EGFR-mutated Stage IB–IIIA non-small cell lung cancer.

Johnson & Johnson announces FDA approval of RYBREVANT® (amivantamab-vmjw) in combination with lazertinib for first-line treatment of adults with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations.

Bristol Myers Squibb announces FDA accelerated approval of ZENBEXUS™ (iberdomide) — the first CELMoD agent approved for multiple myeloma — in combination with daratumumab and dexamethasone, based on a 41% MRD-negative complete response rate in the Phase 3 EXCALIBER-RRMM trial.

Regeneron and Sanofi announce FDA approval of DUPIXENT® (dupilumab) as the first biologic approved for adults with uncontrolled COPD with type 2 inflammation, based on the BOREAS and NOTUS Phase 3 trials showing significant reduction in moderate-to-severe exacerbations.

Orum Therapeutics announces FDA clearance of its IND application for ORM-1153, a first-in-class CD123-GSPT1 degrader-antibody conjugate (DAC), with plans to initiate a Phase 1 study in relapsed/refractory AML and other hematologic malignancies by end of 2026.

Pulnovo Medical announces enrollment of the first two U.S. patients in its PULSE-LHD IDE clinical trial at Henry Ford Hospital, evaluating pulmonary artery denervation (PADN) for pulmonary hypertension associated with left heart disease — a condition affecting 65–80% of all PH cases with no currently approved therapy.

Biogen and Eisai announce FDA approval of a subcutaneous formulation of LEQEMBI (lecanemab-irmb) for early Alzheimer's disease, offering a more convenient at-home administration option for patients.

Pfizer announces FDA approval of Elrexfio (elranatamab-bcmm) for earlier lines of multiple myeloma treatment based on positive Phase 3 MagnetisMM-5 trial data showing superior progression-free survival.

AstraZeneca reports five-year overall survival data from the ADAURA Phase 3 trial showing TAGRISSO (osimertinib) reduces the risk of death by 51% versus placebo in patients with resected EGFR-mutated Stage IB–IIIA non-small cell lung cancer.

Johnson & Johnson announces FDA approval of RYBREVANT® (amivantamab-vmjw) in combination with lazertinib for first-line treatment of adults with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations.

Bristol Myers Squibb announces FDA accelerated approval of ZENBEXUS™ (iberdomide) — the first CELMoD agent approved for multiple myeloma — in combination with daratumumab and dexamethasone, based on a 41% MRD-negative complete response rate in the Phase 3 EXCALIBER-RRMM trial.

Regeneron and Sanofi announce FDA approval of DUPIXENT® (dupilumab) as the first biologic approved for adults with uncontrolled COPD with type 2 inflammation, based on the BOREAS and NOTUS Phase 3 trials showing significant reduction in moderate-to-severe exacerbations.

Orum Therapeutics announces FDA clearance of its IND application for ORM-1153, a first-in-class CD123-GSPT1 degrader-antibody conjugate (DAC), with plans to initiate a Phase 1 study in relapsed/refractory AML and other hematologic malignancies by end of 2026.

Pulnovo Medical announces enrollment of the first two U.S. patients in its PULSE-LHD IDE clinical trial at Henry Ford Hospital, evaluating pulmonary artery denervation (PADN) for pulmonary hypertension associated with left heart disease — a condition affecting 65–80% of all PH cases with no currently approved therapy.

Biogen and Eisai announce FDA approval of a subcutaneous formulation of LEQEMBI (lecanemab-irmb) for early Alzheimer's disease, offering a more convenient at-home administration option for patients.

Pfizer announces FDA approval of Elrexfio (elranatamab-bcmm) for earlier lines of multiple myeloma treatment based on positive Phase 3 MagnetisMM-5 trial data showing superior progression-free survival.

New data from the SELECT trial confirms GLP-1 receptor agonists have cardioprotective effects beyond weight loss, potentially reshaping treatment guidelines for high-risk patients.

Researchers at the Broad Institute report a next-generation base editing platform that dramatically expands the scope of correctable hereditary conditions.

The designation accelerates development of a targeted therapy for non-small cell lung cancer patients with KRAS G12C mutations, affecting approximately 13% of cases.

New data from the SELECT trial confirms GLP-1 receptor agonists have cardioprotective effects beyond weight loss, potentially reshaping treatment guidelines for high-risk patients.

Researchers at the Broad Institute report a next-generation base editing platform that dramatically expands the scope of correctable hereditary conditions.

The designation accelerates development of a targeted therapy for non-small cell lung cancer patients with KRAS G12C mutations, affecting approximately 13% of cases.